scholarly journals Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?

2020 ◽  
Vol 190 (2) ◽  
pp. 135-136 ◽  
Author(s):  
Michele Malagola ◽  
Simona Bernardi ◽  
Nicola Polverelli ◽  
Domenico Russo
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Peripheral Blood ◽  
Residual Disease ◽  
Disease Monitoring ◽  
Minimal Residual Disease Monitoring ◽  
Minimal Residual ◽  
Acute Myeloid

Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia

2008 ◽  
Vol 80 (3) ◽  
pp. 201-207 ◽  
Author(s):  
Mauri M. Hämäläinen ◽  
Veli Kairisto ◽  
Vesa Juvonen ◽  
Janita Johansson ◽  
Jukka Aurén ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Wilms Tumour ◽  
Minimal Residual ◽  
Acute Myeloid

scholarly journals CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection

2017 ◽  
Vol 138 (3) ◽  
pp. 175-181 ◽  
Author(s):  
Adhra Al-Mawali ◽  
Avinash Daniel Pinto ◽  
Shoaib Al-Zadjali
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Minimal Residual Disease ◽  
De Novo ◽  
Residual Disease ◽  
Intention To Treat ◽  
Minimal Residual ◽  
Acute Myeloid

Background/Aims: In CD34-positive acute myeloid leukaemia (AML), the leukaemia-initiating event likely takes place in the CD34+CD38- cell compartment. CD123 has been shown to be a unique marker of leukaemic stem cells within the CD34+CD38- compartment. The aim of this study was to identify the percentage of CD34+CD38-CD123+ cells in AML blasts, AML CD34+CD38- stem cells, and normal and regenerating bone marrow CD34+CD38- stem cells from non-myeloid malignancies. Methods: Thirty-eight adult de novo AML patients with intention to treat were enrolled after the application of inclusion criteria from February 2012 to February 2017. The percentage of the CD34+CD38-CD123+ phenotype in the blast population at diagnosis was determined using a CD45-gating strategy and CD34+ backgating by flow cytometry. We studied the CD34+CD38-CD123+ fraction in AML blasts at diagnosis, and its utility as a unique phenotype for minimal residual disease (MRD) of AML patients. Results: CD123+ cells were present in 97% of AML blasts in patients at diagnosis (median 90%; range 21-99%). CD123+ cells were also present in 97% of the CD34+CD38- compartment (median 0.8164%, range 0.0262-39.7%). Interestingly, CD123 was not present in normal and regenerating CD34+CD38- bone marrow stem cells (range 0.002- 0.067 and 0.004-0.086, respectively). Conclusion: The CD34+CD38-CD123+ phenotype is present in virtually all AML blasts and it may be used as a unique single phenotype for MRD detection in AML patients.

Sign in / Sign up

Export Citation Format

Share Document